Do peptides show up on a drug test?

The question hides two unrelated tests

A drug test at work and a drug test in sport are not versions of the same thing. They are run by different bodies, under different rules, looking for different substances.

One is a panel defined in federal regulation, with a fixed list of what a laboratory is allowed to look for. The other is an anti-doping list that is updated every year and is deliberately open-ended.

The answers they give about this category point in opposite directions, so the useful move is to work out which test you are actually being asked about before looking anything up.

Both documents are published, and both can be read directly. That is what this article does.

The federally regulated workplace panel is a closed list

Federally regulated transportation testing is governed by a rule that states exactly what a laboratory may test for, and the wording is unusually direct.

A laboratory must test for five drugs or classes of drugs, and must not test those specimens for any other drugs. The five are marijuana metabolites, cocaine metabolites, amphetamines, opioids and phencyclidine.

A companion section prints the cutoff table, and its initial-test analytes cover the same territory. They are marijuana metabolites, the cocaine metabolite, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6-acetylmorphine, phencyclidine, amphetamine and methamphetamine, and MDMA and MDA.

This is a closed list stated as a prohibition, not a summary of common practice. That is what makes it usable: the regulation says what is tested for and forbids anything else, so nothing has to be inferred from silence.

The scope matters. This rule governs federally regulated safety-sensitive testing. A private employer sets its own panel, and this site has no published document to read for that, so it makes no claim about it.

The anti-doping list is the opposite kind of document

The list used in tested sport is built to be open-ended, and every structural feature works against the reading most people want from it.

Substances are grouped into classes, each marked with when the prohibition applies. Many classes are prohibited at all times rather than only in competition.

Each class is introduced with wording that it includes, but is not limited to, the substances named. Classes are also extended to other substances with a similar chemical structure or similar biological effects.

The list is updated at least annually. The published version appears in October and comes into force on the first of January, so the document a search engine surfaces may not be the one currently in force.

So the list is not a lookup table where a name either appears or does not. It is a set of definitions with examples attached.

The category that catches unapproved compounds by definition

The first class on the list is the one that matters most for this market, and it does not work by naming things.

It covers any pharmacological substance not addressed by any later section of the list, and with no current approval by any governmental regulatory health authority for human therapeutic use. It gives drugs under pre-clinical or clinical development, discontinued drugs, designer drugs and substances approved only for veterinary use as examples. Everything in it is prohibited at all times.

Read that against this category. A compound with no approval anywhere for human therapeutic use is described by that definition whether or not anyone has written its name down.

The class then says it covers many different substances including but not limited to a short list, and the first named substance on it is BPC-157.

This site grades evidence separately from regulatory status, and neither grade nor status changes what that definition says.

Seven of the sixteen compounds here are named outright

Running this site's sixteen registry compounds against the published list finds seven named in its text.

BPC-157 appears in the non-approved substances class, prohibited at all times. TB-500 appears among growth factors, as thymosin beta-4 and its derivatives. MOTS-c appears under hormone and metabolic modulators, among activators of AMP-activated protein kinase.

Four more appear together in the growth hormone releasing factors section. Sermorelin, tesamorelin and CJC-1295 are given as examples of growth hormone releasing hormone and its analogues, and ipamorelin is given as an example of a growth hormone secretagogue.

That last grouping is worth pausing on, because the secretagogue examples also include ibutamoren. Compounds a buyer would file in different mental categories sit inside the same entry.

Each of these compounds has its own status record and evidence grade on this site, and being named here is a separate fact from both.

The nine that are not named prove nothing

The other nine registry compounds are not named in the list's text, and this site will not report that as a finding.

Every structural feature described above works against that inference. The first class catches unapproved substances without naming them, the classes say they are not limited to what they name, and each extends to substances with similar structure or similar biological effect.

A name missing from a list with an explicit catch-all is not evidence about the substance. It is a fact about the list.

The list carries its own instruction for exactly this situation, and it is the honest end of the inquiry. If you cannot find a substance or method listed, verify its status with your anti-doping organization for accurate and authoritative information.

That is the published route to an answer, and it is the one this site points at rather than reasoning its way to a conclusion it has no standing to reach.

Approval does not clear a compound, and neither does route

Two shortcuts fail here, and both fail in ways that are easy to check.

The first is that an approved drug must be fine. Tesamorelin has an approved product in the United States and is named on the list as an example of a growth hormone releasing hormone analogue. Approval and sport eligibility are answered by different bodies, and neither follows from the other.

The second is that a cream is not an injection. The list addresses this directly in its own guidance on cosmetic products. Topical products may contain prohibited peptides or growth factors, sometimes listed under different names, and those substances are prohibited regardless of the route of administration.

This site has an article on what changing the route does and does not change. For anti-doping purposes the list simply removes route from the question.

A compounded or research-labeled vial cannot be checked at all

There is a further problem specific to how most of this category is sold, and it sits underneath every question above.

The agency has stated that compounded drugs are not approved, and that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

A vial sold under a research-use-only label has still less attached to it, which this site covers in its own article. Neither carries approved labeling stating what is in it and how much.

So a tested athlete holding one of these preparations cannot establish what they took, in what amount, from any document that came with it. That is a problem before any question about the list arises.

Certificates of analysis do not close that gap either, and there is an article here on what one does and does not establish.

What to check, in order

Work out which test is being asked about. A federally regulated workplace panel and an anti-doping panel are different documents with different contents.

For the federally regulated workplace panel, the regulation names five classes and forbids testing those specimens for anything else.

If you are subject to testing in sport, read the current list rather than a summary, and check that it is the edition in force rather than a previous year.

Do not treat the absence of a name as clearance. The first class catches unapproved substances without naming them.

Take an unresolved question to your anti-doping organization, which is what the list itself instructs.

Anything about your own treatment, including whether any compound is appropriate for you, comes from your prescriber and the labeling supplied with your medication.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. The Prohibited List, in force from 1 January 2026 — World Anti-Doping Agency, January 2026
2. 49 CFR 40.82, What drugs do laboratories test for? — Office of the Federal Register, Electronic Code of Federal Regulations, June 2023
3. 49 CFR 40.85, What are the cutoff concentrations for urine drug tests? — Office of the Federal Register, Electronic Code of Federal Regulations, June 2023
4. Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration, September 2025
5. 21 CFR 1308.13, Schedule III — Office of the Federal Register, Electronic Code of Federal Regulations, April 2026